Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury

Menopause

Volumn 13, Issue 1, 2006, Pages 80-86

  Jeanes, Helen L ^a   Wanikiat, Payong ^a,b   Sharif, Isam ^a   Gray, Gillian A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Estrogen; Ischemia; Medroxyprogesterone acetate; Myocardium

Indexed keywords

ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; ANTIESTROGEN; CARDIOTONIC AGENT; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVARIECTOMY; RAT; RAT STRAIN; REPERFUSION INJURY; UREA CYCLE; ANIMAL; BODY WEIGHT; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HEART MUSCLE; HISTOLOGY; METABOLISM; NECROSIS; NEUTROPHIL; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; UTERUS; WISTAR RAT;

ANIMALS; BODY WEIGHT; CARDIOTONIC AGENTS; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; MEDROXYPROGESTERONE 17-ACETATE; MYOCARDIUM; NECROSIS; NEUTROPHILS; ORGAN SIZE; OVARIECTOMY; PEROXIDASE; RATS; RATS, WISTAR; REPERFUSION INJURY; UTERUS;

EID: 33646005517     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000196593.44335.eb     Document Type: Article

References (46)

1. Pelzer T, Shamim A, Neyses L. Estrogen effects in the heart. Mol Cell Biochem 1996;160-161:307-313.
2. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
3. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-1109.
4. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
5. Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 2004;44:789-795.
6. Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745-5756.
7. Oishi A, Ohmichi M, Takahashi K, et al. Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004;324:193-198.
8. Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol 2004;24:1171-1179.
9. Squadrito F, Altavilla D, Squadrito G, et al. 17Beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. Eur J Pharmacol 1997;335:185-192.
10. Kolodgie FD, Farb A, Litovsky SH, et al. Myocardial protection of contractile function after global ischemia by physiologic estrogen replacement in the ovariectomized rat. J Mol Cell Cardiol 1997;29:2403-2414.
11. Zhai P, Eurell TE, Cotthaus R, Jeffery EH, Bahr JM, Gross DR. Effect of estrogen on global myocardial ischemia-reperfusion injury in female rats. Am J Physiol Heart Circ Physiol 2000;279:H2766-H2775.
12. Fink G, Sumner BE, McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol 1998;25:764-775.
13. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985;14:157-167.
14. Rubanyi G, Kovach AG. Effect of hypoxia on mechanical properties of isolated rat heart: comparison of the effects of hypoxic and histotoxic hypoxia. Acta Physiol Acad Sci Hung 1980;55:215-225.
15. de Lorgeril M, Rousseau G, Basmadjian A, Latour JG. Lignocaine in experimental myocardial infarction: failure to prevent neutrophil accumulation and ventricular fibrillation and to reduce infarct size. Cardiovasc Res 1988;22:439-446.
16. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998:19:61-109.
17. Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
18. Herrington DM, Reboussin DM, Brosnihan KB. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
19. Langer RD. Hormone replacement and the prevention of cardiovascular disease. Am J Cardiol 2002;89:36E-46E [discussion 46E].
20. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-78.
21. Falkeborn M, Persson I, Adami HO. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-828.
22. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 2002;33:1685-1691.
23. Gorodeski GI, Yang T, Levy MN, Goldfarb J, Utian WH. Modulation of coronary vascular resistance in female rabbits by estrogen and progesterone. J Soc Gynecol Invest 1998;5:197-202.
24. Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab 1998;83:649-659.
25. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-221.
26. Sullivan TR Jr, Karas RH, Aronovitz M, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995;96:2482-2488.
27. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 1996;94:2221-2227.
28. Lefer AM. Physiologic and pathophysiologic role of cyclooxygenase metabolites of arachidonic acid in circulatory disease states. Cardiovasc Clin 1987;18:85-99.
29. Jennings RB, Reimer KA. Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation 1983;68(2 Pt 2):I25-I36.
30. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-163.
31. Premaratne S, Limm W, Mugiishi MM, Piette LH, McNamara JJ. Quantitative assessment of free-radical generation during ischemia and reperfusion in the isolated rabbit heart. Coronary Artery Dis 1993;4:1093-1096.
32. Hudson KF. A phenomenon of paradox: myocardial reperfusion injury. Heart Lung 1994;23:384-393.
33. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992;48:276-308.
34. Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862-867.
35. Lucchesi BR. Modulation of leukocyte-mediated myocardial reperfusion injury. Ann Rev Physiol 1990;52:561-576.
36. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
37. Rubanyi GM, Freay AD, Kauser K, et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta: gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997;99:2429-2437.
38. Davies MG, Fulton GJ, Hagen PO. Clinical biology of nitric oxide. Br J Surg 1995;82:1598-1610.
39. Babiker FA, De Windt LJ, van Eickels M, Grohe C, Meyer R, Doevendans PA. Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res 2002;53:709-719.
40. Beckett T, Tchernof A, Toth MJ. Effect of ovariectomy and estradiol replacement on skeletal muscle enzyme activity in female rats. Metabolism 2002;51:1397-1401.
41. Bigsby RM, Caperell-Grant A, Berry N, Nephew K, Lubahn D. Estrogen induces a systemic growth factor through an estrogen receptor-alpha-dependent mechanism. Biol Reprod 2004;70:178-183.
42. Di Carlo F, Racca S, Conti G, et al. Effects of long-term administration of high doses of medroxyprogesterone acetate on hormone receptors and target organs in the female rat. J Endocrinol 1984;103:287-293.
43. Di Carlo F, Gallo E, Conti G, Racca S. Changes in the binding of oestradiol to uterine oestrogen receptors induced by some progesterone and 19-nor-testosterone derivatives. J Endocrinol 1983;98:385-389.
44. Chwalisz K, Stockemann K, Fritzemeier KH, Fuhrmann U. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum Reprod Update 1998;4:570-583.
45. Chataigneau T, Zerr M, Chataigneau M, et al. Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats. Menopause 2004;11:255-263.
46. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001;104:1773-1778.